This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Construction Data, Q1 Earnings In Focus
by Zacks Equity Research
New Construction Data, Q1 Earnings In Focus
Tax Day Not So Taxing (for Corporations, Housing)
by Mark Vickery
Strength in Q1 earnings season, at least in these early stages, has helped bolster market indexes. This continues ahead of Tuesday's market open.
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
J&J (JNJ) Beats on Q1 Earnings & Sales, Ups 2018 Sales View
by Zacks Equity Research
J&J (JNJ) beat estimates for both earnings and sales in the first quarter of 2018. It maintained the previously issued earnings guidance for 2018 while increasing the sales range.
5 of the Best Big Cap Earnings Charts
by Tracey Ryniec
These big cap companies almost always beat the estimate on earnings but will that change in 2018?
Here's Why Geron Stock Surged More Than 90% in 6 Months
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
Karyopharm's Myeloma Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.
4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings
by Tirthankar Chakraborty
The recent tax code overhaul and a strengthening economy could certainly help blue-chip companies make more money this upcoming earnings season.
4 Drug/Biotech Stocks to Buy Ahead of World Health Day
by Indrajit Bandyopadhyay
Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
by Zacks Equity Research
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
Wall Street Brushes Off Trade War Fears: Top 5 Gainers
by Tirthankar Chakraborty
The Dow climbed more than 700 points after investors downplayed fears over tariffs announced by both China and the United States.
Allergan's Vraylar Meets Endpoints in Bipolar I Phase III
by Zacks Equity Research
Allergan (AGN) along with partner Gedeon Richter posts positive top-line results from the third pivotal study, analyzing label expansion of the schizophrenia drug Vraylar to cure bipolar I depression.
AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use
by Zacks Equity Research
AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.
Shire's Stock Continues to Rise as Takeda Sets Eyes On it
by Zacks Equity Research
Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Intel, Procter & Gamble, Caterpillar and Halliburton
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Intel, Procter & Gamble, Caterpillar and Halliburton
Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Intel (INTC) and Procter & Gamble (PG).
Protagonist Therapeutics Stalls Ulcerative Colitis Study
by Zacks Equity Research
Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.
Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod
by Zacks Equity Research
Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.
Novartis Gets Positive CHMP Opinion on Biosimilar Remicade
by Zacks Equity Research
The CHMP gave a positive opinion to Novartis (NVS) proposed biosimilar of Remicade for all of the branded drug's indications. A decision from the EMA is expected shortly.
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome
by Zacks Equity Research
AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting
4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18
by Zacks Equity Research
Glaxo (GSK) has a Zacks Rank #2 (Buy). Its shares have outperformed the industry this year so far. Earnings estimates are also on the rise.